Eintrag weiter verarbeiten
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration: Insights From the Vete...
Gespeichert in:
| Zeitschriftentitel: | Circulation |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Circulation, 139, 2019, 22, S. 2502-2512 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. |
|---|---|
| author |
Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. |
| spellingShingle |
Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. Circulation Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration Physiology (medical) Cardiology and Cardiovascular Medicine |
| author_sort |
perino, alexander c. |
| spelling |
Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/circulationaha.118.038988 <jats:sec> <jats:title>Background:</jats:title> <jats:p>Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association with outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p> We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden. We included patients with cardiac implantable electronic devices and remote monitoring from 2011 to 2014, CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score ≥2, and no prior stroke or OAC receipt in the preceding 2 years. We determined the proportion of patients prescribed OAC within 90 days after new device-detected AF across a range of AF thresholds (≥6 minutes to >24 hours) and examined site variation in OAC prescription. We used multivariable Cox proportional hazards regressions to determine the association of OAC prescription with stroke by device-detected AF burden. </jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%), 3263 (32%), and 2469 (24%) had device-detected AF >6 minutes, >1 hour, >6 hours, and >24 hours, respectively. For device-detected AF >1 hour, 1712 patients met inclusion criteria (72±10 years; 1.5% female; CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score 4.0±1.4; HAS-BLED score 2.6±1.1). The proportion receiving OAC varied based on device-detected AF burden (≥6 minutes: 272/2101 [13%]; >1 hour: 273/1712 [16%]; >6 hours: 263/1279 [21%]; >24 hours: 224/818 [27%]). Across 52 sites (N=1329 patients), there was substantial site-level variation in OAC prescription after device-detected AF >1 hour (median, 16%; range, 3%–67%; median odds ratio, 1.56 [95% credible interval, 1.49–1.71]). In adjusted models, OAC prescription after device-detected AF >24 hours was associated with reduced stroke risk (hazard ratio, 0.28; 95% CI, 0.10–0.81; <jats:italic>P</jats:italic> =0.02), although the propensity-adjusted model was significant when AF lasted at least 6 minutes. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Among veterans with cardiac implantable electronic devices, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF, with low rates of treatment overall, even for episodes that last >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings.</jats:p> </jats:sec> Insights From the Veterans Health Administration Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration Circulation |
| doi_str_mv |
10.1161/circulationaha.118.038988 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM4OTg4 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM4OTg4 |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| issn |
0009-7322 1524-4539 |
| issn_str_mv |
0009-7322 1524-4539 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
perino2019practicevariationinanticoagulationprescriptionandoutcomesafterdevicedetectedatrialfibrillationinsightsfromtheveteranshealthadministrationinsightsfromtheveteranshealthadministration |
| publishDateSort |
2019 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Circulation |
| source_id |
49 |
| title_sub |
Insights From the Veterans Health Administration |
| title |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_unstemmed |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_full |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_fullStr |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_full_unstemmed |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_short |
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_sort |
practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation : insights from the veterans health administration |
| topic |
Physiology (medical) Cardiology and Cardiovascular Medicine |
| url |
http://dx.doi.org/10.1161/circulationaha.118.038988 |
| publishDate |
2019 |
| physical |
2502-2512 |
| description |
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association with outcomes.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>
We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden. We included patients with cardiac implantable electronic devices and remote monitoring from 2011 to 2014, CHA
<jats:sub>2</jats:sub>
DS
<jats:sub>2</jats:sub>
-VASc score ≥2, and no prior stroke or OAC receipt in the preceding 2 years. We determined the proportion of patients prescribed OAC within 90 days after new device-detected AF across a range of AF thresholds (≥6 minutes to >24 hours) and examined site variation in OAC prescription. We used multivariable Cox proportional hazards regressions to determine the association of OAC prescription with stroke by device-detected AF burden.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>
Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%), 3263 (32%), and 2469 (24%) had device-detected AF >6 minutes, >1 hour, >6 hours, and >24 hours, respectively. For device-detected AF >1 hour, 1712 patients met inclusion criteria (72±10 years; 1.5% female; CHA
<jats:sub>2</jats:sub>
DS
<jats:sub>2</jats:sub>
-VASc score 4.0±1.4; HAS-BLED score 2.6±1.1). The proportion receiving OAC varied based on device-detected AF burden (≥6 minutes: 272/2101 [13%]; >1 hour: 273/1712 [16%]; >6 hours: 263/1279 [21%]; >24 hours: 224/818 [27%]). Across 52 sites (N=1329 patients), there was substantial site-level variation in OAC prescription after device-detected AF >1 hour (median, 16%; range, 3%–67%; median odds ratio, 1.56 [95% credible interval, 1.49–1.71]). In adjusted models, OAC prescription after device-detected AF >24 hours was associated with reduced stroke risk (hazard ratio, 0.28; 95% CI, 0.10–0.81;
<jats:italic>P</jats:italic>
=0.02), although the propensity-adjusted model was significant when AF lasted at least 6 minutes.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>Among veterans with cardiac implantable electronic devices, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF, with low rates of treatment overall, even for episodes that last >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings.</jats:p>
</jats:sec> |
| container_issue |
22 |
| container_start_page |
2502 |
| container_title |
Circulation |
| container_volume |
139 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346474897473536 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:39:58.399Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Practice+Variation+in+Anticoagulation+Prescription+and+Outcomes+After+Device-Detected+Atrial+Fibrillation+%3A+Insights+From+the+Veterans+Health+Administration&rft.date=2019-05-28&genre=article&issn=1524-4539&volume=139&issue=22&spage=2502&epage=2512&pages=2502-2512&jtitle=Circulation&atitle=Practice+Variation+in+Anticoagulation+Prescription+and+Outcomes+After+Device-Detected+Atrial+Fibrillation+%3A+Insights+From+the+Veterans+Health+Administration&aulast=Turakhia&aufirst=Mintu+P.&rft_id=info%3Adoi%2F10.1161%2Fcirculationaha.118.038988&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346474897473536 |
| author | Perino, Alexander C., Fan, Jun, Askari, Mariam, Heidenreich, Paul A., Keung, Edmund, Raitt, Merritt H., Piccini, Jonathan P., Ziegler, Paul D., Turakhia, Mintu P. |
| author_facet | Perino, Alexander C., Fan, Jun, Askari, Mariam, Heidenreich, Paul A., Keung, Edmund, Raitt, Merritt H., Piccini, Jonathan P., Ziegler, Paul D., Turakhia, Mintu P., Perino, Alexander C., Fan, Jun, Askari, Mariam, Heidenreich, Paul A., Keung, Edmund, Raitt, Merritt H., Piccini, Jonathan P., Ziegler, Paul D., Turakhia, Mintu P. |
| author_sort | perino, alexander c. |
| container_issue | 22 |
| container_start_page | 2502 |
| container_title | Circulation |
| container_volume | 139 |
| description | <jats:sec> <jats:title>Background:</jats:title> <jats:p>Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association with outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p> We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden. We included patients with cardiac implantable electronic devices and remote monitoring from 2011 to 2014, CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score ≥2, and no prior stroke or OAC receipt in the preceding 2 years. We determined the proportion of patients prescribed OAC within 90 days after new device-detected AF across a range of AF thresholds (≥6 minutes to >24 hours) and examined site variation in OAC prescription. We used multivariable Cox proportional hazards regressions to determine the association of OAC prescription with stroke by device-detected AF burden. </jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%), 3263 (32%), and 2469 (24%) had device-detected AF >6 minutes, >1 hour, >6 hours, and >24 hours, respectively. For device-detected AF >1 hour, 1712 patients met inclusion criteria (72±10 years; 1.5% female; CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score 4.0±1.4; HAS-BLED score 2.6±1.1). The proportion receiving OAC varied based on device-detected AF burden (≥6 minutes: 272/2101 [13%]; >1 hour: 273/1712 [16%]; >6 hours: 263/1279 [21%]; >24 hours: 224/818 [27%]). Across 52 sites (N=1329 patients), there was substantial site-level variation in OAC prescription after device-detected AF >1 hour (median, 16%; range, 3%–67%; median odds ratio, 1.56 [95% credible interval, 1.49–1.71]). In adjusted models, OAC prescription after device-detected AF >24 hours was associated with reduced stroke risk (hazard ratio, 0.28; 95% CI, 0.10–0.81; <jats:italic>P</jats:italic> =0.02), although the propensity-adjusted model was significant when AF lasted at least 6 minutes. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Among veterans with cardiac implantable electronic devices, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF, with low rates of treatment overall, even for episodes that last >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings.</jats:p> </jats:sec> |
| doi_str_mv | 10.1161/circulationaha.118.038988 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjdWxhdGlvbmFoYS4xMTguMDM4OTg4 |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2019 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0009-7322, 1524-4539 |
| issn_str_mv | 0009-7322, 1524-4539 |
| language | English |
| last_indexed | 2024-03-01T17:39:58.399Z |
| match_str | perino2019practicevariationinanticoagulationprescriptionandoutcomesafterdevicedetectedatrialfibrillationinsightsfromtheveteranshealthadministrationinsightsfromtheveteranshealthadministration |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 2502-2512 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Circulation |
| source_id | 49 |
| spelling | Perino, Alexander C. Fan, Jun Askari, Mariam Heidenreich, Paul A. Keung, Edmund Raitt, Merritt H. Piccini, Jonathan P. Ziegler, Paul D. Turakhia, Mintu P. 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/circulationaha.118.038988 <jats:sec> <jats:title>Background:</jats:title> <jats:p>Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice variation in response to new device-detected AF and the association with outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p> We performed a retrospective cohort study using data from the Veterans Health Administration linked to remote monitoring data that included day-level AF burden. We included patients with cardiac implantable electronic devices and remote monitoring from 2011 to 2014, CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score ≥2, and no prior stroke or OAC receipt in the preceding 2 years. We determined the proportion of patients prescribed OAC within 90 days after new device-detected AF across a range of AF thresholds (≥6 minutes to >24 hours) and examined site variation in OAC prescription. We used multivariable Cox proportional hazards regressions to determine the association of OAC prescription with stroke by device-detected AF burden. </jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%), 3263 (32%), and 2469 (24%) had device-detected AF >6 minutes, >1 hour, >6 hours, and >24 hours, respectively. For device-detected AF >1 hour, 1712 patients met inclusion criteria (72±10 years; 1.5% female; CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc score 4.0±1.4; HAS-BLED score 2.6±1.1). The proportion receiving OAC varied based on device-detected AF burden (≥6 minutes: 272/2101 [13%]; >1 hour: 273/1712 [16%]; >6 hours: 263/1279 [21%]; >24 hours: 224/818 [27%]). Across 52 sites (N=1329 patients), there was substantial site-level variation in OAC prescription after device-detected AF >1 hour (median, 16%; range, 3%–67%; median odds ratio, 1.56 [95% credible interval, 1.49–1.71]). In adjusted models, OAC prescription after device-detected AF >24 hours was associated with reduced stroke risk (hazard ratio, 0.28; 95% CI, 0.10–0.81; <jats:italic>P</jats:italic> =0.02), although the propensity-adjusted model was significant when AF lasted at least 6 minutes. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Among veterans with cardiac implantable electronic devices, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF, with low rates of treatment overall, even for episodes that last >24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF >24 hours. Randomized trials are needed to confirm these observational findings.</jats:p> </jats:sec> Insights From the Veterans Health Administration Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration Circulation |
| spellingShingle | Perino, Alexander C., Fan, Jun, Askari, Mariam, Heidenreich, Paul A., Keung, Edmund, Raitt, Merritt H., Piccini, Jonathan P., Ziegler, Paul D., Turakhia, Mintu P., Circulation, Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration, Physiology (medical), Cardiology and Cardiovascular Medicine |
| title | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_full | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_fullStr | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_full_unstemmed | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_short | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| title_sort | practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation : insights from the veterans health administration |
| title_sub | Insights From the Veterans Health Administration |
| title_unstemmed | Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation : Insights From the Veterans Health Administration |
| topic | Physiology (medical), Cardiology and Cardiovascular Medicine |
| url | http://dx.doi.org/10.1161/circulationaha.118.038988 |